Show simple item record

dc.contributor.authorWest, Nicholas P
dc.contributor.authorHorn, Peggy L
dc.contributor.authorPyne, David B
dc.contributor.authorGebski, Val J
dc.contributor.authorLahtinen, Sampo J
dc.contributor.authorFricker, Peter A
dc.contributor.authorCripps, Allan W
dc.date.accessioned2017-07-27T01:30:23Z
dc.date.available2017-07-27T01:30:23Z
dc.date.issued2014
dc.date.modified2014-05-27T22:27:02Z
dc.identifier.issn0261-5614
dc.identifier.doi10.1016/j.clnu.2013.10.002
dc.identifier.urihttp://hdl.handle.net/10072/57191
dc.description.abstractBACKGROUND & AIMS: To examine the effect of supplementation with probiotics on respiratory and gastrointestinal illness in healthy active men and women. METHODS: A randomised double-blind placebo-controlled trial was conducted. Four hundred and sixty five participants (241 males; age 35ౠ12๠(meanౠSD) and 224 females; age 36ౠ12๩ were assigned to one of three groups: Group 1 - Bifidobacterium animalis subsp. lactis Bl-04 (Bl-04) 2.0נ10(9)colony forming units per day, CFU per day, Group 2 - Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07 (NCFM & Bi-07) 5נ10(9)ÆU each per day) or Group 3 - placebo mixed in a drink. RESULTS: The risk of an upper respiratory illness episode was significantly lower in the Bl-04 group (hazard ratio 0.73; 95% confidence interval 0.55-0.95; Pའ0.022) compared to placebo. There was no significant difference in illness risk between the NCFM & Bi-07 group (hazard ratio 0.81; 0.62-1.08; Pའ0.15) and the placebo group. There was a 0.7 and 0.9 month delay in the median time to an illness episode in the Bl-04 and NCFM & Bi-07 groups respectively compared to placebo (placebo 2.5 months; Bl-04 3.2 months; NCFM & Bi-07 3.4 months). There were insufficient GI illness episodes for analysis. The NCFM & Bi-07 group but not the Bl-04 group undertook significantly more physical activity (8.5%; 6.7%-10%; P༠0.003) than the placebo group. CONCLUSION: The probiotic Bl-04 appears to be a useful nutritional supplement in reducing the risk of URTI in healthy physically-active adults. TRIAL REGISTRATION: Australia New Zealand Clinical Trials Registry: Number ACTRN12611000130965.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent386137 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.publisher.placeNetherlands
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom581
dc.relation.ispartofpageto587
dc.relation.ispartofissue4
dc.relation.ispartofjournalClinical Nutrition
dc.relation.ispartofvolume33
dc.rights.retentionY
dc.subject.fieldofresearchTraditional, complementary and integrative medicine not elsewhere classified
dc.subject.fieldofresearchNutrition and dietetics
dc.subject.fieldofresearchcode420899
dc.subject.fieldofresearchcode3210
dc.titleProbiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Allied Health Sciences
gro.rights.copyright© 2013 Elsevier. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
gro.date.issued2013
gro.hasfulltextFull Text
gro.griffith.authorPyne, David B.
gro.griffith.authorCripps, Allan W.
gro.griffith.authorWest, Nic P.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record